Guidelines for treatment of HIV infected adults in Europe
News
9 April 2019
De-simplification for cost savings
321 HIV-infected Canadian patients on Triumeq® were offered to voluntarily switch to Tivicay® in combination with generic abacavir/lamivudine from January 2015 to January 2018. No incentives were provided. Read more
28 June 2018
Efavirenz 5 days per week
The BREATHER study was a non-inferiority trial of efavirenz based antiretroviral treatment 5 days a week compared to daily treatment in children, adolescents and young adults. After 48 weeks the 5 days therapy was shown to be non-inferior to daily... Läs mer
EACS Guidelines
Magazine